Personalis, Inc. 8K

Personalis, Inc. announced strong Q2 2026 revenue and clinical volume growth, expanded Medicare coverage and clinical data for its NeXT Personal MRD assay, continued significant net losses but strong cash reserves, and, due to its pending merger with Tempus AI, Inc., will stop providing financial guidance and quarterly earnings calls.

On August 4, 2026, Personalis, Inc. reported its financial and operational results for the quarter ended June 30, 2026, highlighting a 30% year-over-year increase in total revenue to $22.4 million, driven by strong growth in pharma testing services and a 442% surge in clinical revenue to $2.6 million as clinical test volumes rose 199% to 10,384 tests following expanded Medicare coverage for the NeXT Personal MRD assay in additional oncology indications. Despite this growth, the company reported a net loss of $31.7 million for the quarter and ended with a solid liquidity position of approximately $212.7 million in cash, cash equivalents, and short-term investments. Operationally, Personalis secured new Medicare coverage for NeXT Personal in immunotherapy monitoring for late-stage solid tumors and for monitoring neoadjuvant therapy response in certain Stage II–III breast cancers, presented strong performance data in colorectal cancer recurrence detection and sub-10 ppm sensitivity in lung cancer, and reiterated its strategy to “Win-in-MRD.” In light of the previously announced Agreement and Plan of Merger with Tempus AI, Inc. on July 20, 2026, Personalis also stated that it will cease providing financial guidance and will not conduct quarterly earnings conference calls going forward.

Filing Facts

CIK

1527753

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-332748

Alert Tier

7